211 related articles for article (PubMed ID: 17676831)
1. Dopamine/serotonin receptor ligands. 16.(1) Expanding dibenz[d,g]azecines to 11- and 12-membered homologues. Interaction with dopamine D(1)-D(5) receptors.
Enzensperger C; Müller FK; Schmalwasser B; Wiecha P; Traber H; Lehmann J
J Med Chem; 2007 Sep; 50(18):4528-33. PubMed ID: 17676831
[TBL] [Abstract][Full Text] [Related]
2. Dopamine/serotonin receptor ligands. 12(1): SAR studies on hexahydro-dibenz[d,g]azecines lead to 4-chloro-7-methyl-5,6,7,8,9,14-hexahydrodibenz[d,g]azecin-3-ol, the first picomolar D5-selective dopamine-receptor antagonist.
Mohr P; Decker M; Enzensperger C; Lehmann J
J Med Chem; 2006 Mar; 49(6):2110-6. PubMed ID: 16539400
[TBL] [Abstract][Full Text] [Related]
3. Dopamine/serotonin receptor ligands. 10: SAR Studies on azecine-type dopamine receptor ligands by functional screening at human cloned D1, D2L, and D5 receptors with a microplate reader based calcium assay lead to a novel potent D1/D5 selective antagonist.
Hoefgen B; Decker M; Mohr P; Schramm AM; Rostom SA; El-Subbagh H; Schweikert PM; Rudolf DR; Kassack MU; Lehmann J
J Med Chem; 2006 Jan; 49(2):760-9. PubMed ID: 16420061
[TBL] [Abstract][Full Text] [Related]
4. Ring expansions of tetrahydroprotoberberines and related dibenzo[c,g]azecines modulate the dopamine receptor subtype affinity and selectivity.
Schulze M; Siol O; Meise W; Lehmann J; Enzensperger C
Arch Pharm (Weinheim); 2010 Apr; 343(4):207-14. PubMed ID: 20222063
[TBL] [Abstract][Full Text] [Related]
5. Dibenzazecine compounds with a novel dopamine/5HT2A receptor profile and 3D-QSAR analysis.
Hamacher A; Weigt M; Wiese M; Hoefgen B; Lehmann J; Kassack MU
BMC Pharmacol; 2006 Sep; 6():11. PubMed ID: 16978403
[TBL] [Abstract][Full Text] [Related]
6. Dopamine/serotonin receptor ligands. 13: Homologization of a benzindoloazecine-type dopamine receptor antagonist modulates the affinities for dopamine D(1)-D(5) receptors.
Enzensperger C; Lehmann J
J Med Chem; 2006 Oct; 49(21):6408-11. PubMed ID: 17034146
[TBL] [Abstract][Full Text] [Related]
7. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
[TBL] [Abstract][Full Text] [Related]
8. Dopamine/serotonin receptor ligands. Part 15: Oxygenation of the benz-indolo-azecine LE 300 leads to novel subnanomolar dopamine D1/D5 antagonists.
Enzensperger C; Kilian S; Ackermann M; Koch A; Kelch K; Lehmann J
Bioorg Med Chem Lett; 2007 Mar; 17(5):1399-402. PubMed ID: 17188870
[TBL] [Abstract][Full Text] [Related]
9. Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities?
Schulze M; Müller FK; Mason JM; Görls H; Lehmann J; Enzensperger C
Bioorg Med Chem; 2009 Oct; 17(19):6898-907. PubMed ID: 19744859
[TBL] [Abstract][Full Text] [Related]
10. Phenylpiperazinylmethylheterocycle derivatives: synthesis and dopamine receptor binding profiles.
Abadi AH
Arch Pharm (Weinheim); 2004 Jul; 337(7):383-90. PubMed ID: 15237388
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and pharmacological evaluation of thiazole and isothiazole derived apomorphines.
Sipos A; Mueller FK; Lehmann J; Berényi S; Antus S
Arch Pharm (Weinheim); 2009 Oct; 342(10):557-68. PubMed ID: 19714675
[TBL] [Abstract][Full Text] [Related]
12. Dopamine receptor ligands. Part 18: (1) modification of the structural skeleton of indolobenzazecine-type dopamine receptor antagonists.
Robaa D; Enzensperger C; Abul Azm Sel D; El Khawass el S; El Sayed O; Lehmann J
J Med Chem; 2010 Mar; 53(6):2646-50. PubMed ID: 20180564
[TBL] [Abstract][Full Text] [Related]
13. [3H] A-369508 ([2-[4-(2-cyanophenyl)-1-piperazinyl]-N-(3-methylphenyl) acetamide): an agonist radioligand selective for the dopamine D4 receptor.
Moreland RB; Terranova MA; Chang R; Uchic ME; Matulenko MA; Surber BW; Stewart AO; Brioni JD
Eur J Pharmacol; 2004 Aug; 497(2):147-54. PubMed ID: 15306199
[TBL] [Abstract][Full Text] [Related]
14. Penile erection and yawning induced by dopamine D2-like receptor agonists in rats: influence of strain and contribution of dopamine D2, but not D3 and D4 receptors.
Depoortère R; Bardin L; Rodrigues M; Abrial E; Aliaga M; Newman-Tancredi A
Behav Pharmacol; 2009 Jul; 20(4):303-11. PubMed ID: 19584712
[TBL] [Abstract][Full Text] [Related]
15. Dopamine D1/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists.
Wu WL; Burnett DA; Spring R; Greenlee WJ; Smith M; Favreau L; Fawzi A; Zhang H; Lachowicz JE
J Med Chem; 2005 Feb; 48(3):680-93. PubMed ID: 15689153
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and binding affinity of new 1,4-disubstituted triazoles as potential dopamine D(3) receptor ligands.
Insua I; Alvarado M; Masaguer CF; Iglesias A; Brea J; Loza MI; Carro L
Bioorg Med Chem Lett; 2013 Oct; 23(20):5586-91. PubMed ID: 24012118
[TBL] [Abstract][Full Text] [Related]
17. Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 receptor selectivity.
Wittig TW; Decker M; Lehmann J
J Med Chem; 2004 Aug; 47(17):4155-8. PubMed ID: 15293986
[TBL] [Abstract][Full Text] [Related]
18. Dopamine/serotonin receptor ligands. Part 17: a cross-target SAR approach: affinities of azecine-styled ligands for 5-HT(2A) versus D1 and D2 receptors.
Enzensperger C; Görnemann T; Pertz HH; Lehmann J
Bioorg Med Chem Lett; 2008 Jul; 18(13):3809-13. PubMed ID: 18534847
[TBL] [Abstract][Full Text] [Related]
19. Dopamine receptor subtypes in the human pulmonary arterial tree.
Ricci A; Mignini F; Tomassoni D; Amenta F
Auton Autacoid Pharmacol; 2006 Oct; 26(4):361-9. PubMed ID: 16968475
[TBL] [Abstract][Full Text] [Related]
20. Dopamine/serotonin receptor ligands, part III [1]: synthesis and biological activities of 7, 7'-alkylene-bis-6, 7, 8, 9, 14, 15-hexahydro-5H-benz[d]indolo[2, 3-g]azecines -- application of the bivalent ligand approach to a novel type of dopamine receptor antagonist.
Abadi AH; Lankow S; Hoefgen B; Decker M; Kassack MU; Lehmann J
Arch Pharm (Weinheim); 2002 Aug; 335(8):367-73. PubMed ID: 12397620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
